Refocus Group: Refocus Group Completes Phase 3 Clinical Trial on the VisAbility Micro-Insert System for Presbyopia; Raises Additional Funding / 360 Patient Surgeries Completed; 12-Month Follow-Up in Process
DALLAS, TX -- (Marketwired) -- 05/05/16 -- Refocus Group, a pioneer in vision-correcting technology, announced today that it has completed the enrollment of its Phase 3 clinical trial on the VisAb...
Read full article »
Refocus Group, Inc. is a medical device company engaged in the research and development of treatments for human vision disorders.
Read more